| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2926 |
| Trial ID | NCT05230953 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | mRNA-1273|Elasomeran|Spikevax |
| Location approved | UK, Canada, Taiwan, Switzerland, Japan, EU, Australia, South Korea, Singapore, US |
| Phase | Phase3 |
| Recruitment status | Active, Not Recruiting |
| Title | Fourth COVID-19 Vaccine Dose- mRNA1273 - the Sheba HCW Cohort |
| Year | 2022 |
| Country | Israel |
| Company sponsor | Sheba Medical Center |
| Other ID(s) | 9035-21 |
| Vector information | |||
|
|||
| Cohort1: mRNA1273 | |||||||||
|
|||||||||
| Cohort2: No Intervention | |||||||||
|
|||||||||
| Cohort3: BNT162b2 | |||||||||
|
|||||||||